JP2019528061A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528061A5
JP2019528061A5 JP2019508259A JP2019508259A JP2019528061A5 JP 2019528061 A5 JP2019528061 A5 JP 2019528061A5 JP 2019508259 A JP2019508259 A JP 2019508259A JP 2019508259 A JP2019508259 A JP 2019508259A JP 2019528061 A5 JP2019528061 A5 JP 2019528061A5
Authority
JP
Japan
Prior art keywords
cancer
seq
amino acid
acid sequence
antigen recognition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019508259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528061A (ja
JP6964351B2 (ja
Filing date
Publication date
Priority claimed from DE102016115246.3A external-priority patent/DE102016115246C5/de
Application filed filed Critical
Publication of JP2019528061A publication Critical patent/JP2019528061A/ja
Publication of JP2019528061A5 publication Critical patent/JP2019528061A5/ja
Priority to JP2021128303A priority Critical patent/JP2021184729A/ja
Application granted granted Critical
Publication of JP6964351B2 publication Critical patent/JP6964351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019508259A 2016-08-17 2017-07-04 新規t細胞受容体およびそれを用いた免疫療法 Active JP6964351B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021128303A JP2021184729A (ja) 2016-08-17 2021-08-04 新規t細胞受容体およびそれを用いた免疫療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662376059P 2016-08-17 2016-08-17
US62/376,059 2016-08-17
DE102016115246.3 2016-08-17
DE102016115246.3A DE102016115246C5 (de) 2016-08-17 2016-08-17 Neue t-zellrezeptoren und deren verwendung in immuntherapie
US201662376632P 2016-08-18 2016-08-18
US62/376,632 2016-08-18
PCT/EP2017/066630 WO2018033291A1 (en) 2016-08-17 2017-07-04 T cell receptors and immune therapy using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021128303A Division JP2021184729A (ja) 2016-08-17 2021-08-04 新規t細胞受容体およびそれを用いた免疫療法

Publications (3)

Publication Number Publication Date
JP2019528061A JP2019528061A (ja) 2019-10-10
JP2019528061A5 true JP2019528061A5 (enExample) 2020-02-20
JP6964351B2 JP6964351B2 (ja) 2021-11-10

Family

ID=60419980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019508259A Active JP6964351B2 (ja) 2016-08-17 2017-07-04 新規t細胞受容体およびそれを用いた免疫療法
JP2021128303A Pending JP2021184729A (ja) 2016-08-17 2021-08-04 新規t細胞受容体およびそれを用いた免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021128303A Pending JP2021184729A (ja) 2016-08-17 2021-08-04 新規t細胞受容体およびそれを用いた免疫療法

Country Status (18)

Country Link
US (2) US10550182B2 (enExample)
EP (1) EP3500593B1 (enExample)
JP (2) JP6964351B2 (enExample)
CN (1) CN109563149A (enExample)
AU (2) AU2017312361B2 (enExample)
BR (1) BR112019001922A2 (enExample)
CA (1) CA3031995A1 (enExample)
CR (1) CR20190095A (enExample)
DE (1) DE102016115246C5 (enExample)
DK (1) DK3500593T3 (enExample)
LT (1) LT3500593T (enExample)
MA (1) MA45976B1 (enExample)
MX (1) MX395287B (enExample)
PE (1) PE20190477A1 (enExample)
RS (1) RS62498B1 (enExample)
SG (1) SG11201900955VA (enExample)
TW (1) TWI775768B (enExample)
WO (1) WO2018033291A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
ZA201900664B (en) * 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
JP7037577B2 (ja) * 2017-03-15 2022-03-16 フレッド ハッチンソン キャンサー リサーチ センター 高親和性mage-a1特異的tcr及びその使用
JP7385556B2 (ja) 2017-09-01 2023-11-22 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Bcma抗原に特異的な免疫原性ペプチドおよびその使用
KR20250052472A (ko) 2017-11-06 2025-04-18 이매틱스 바이오테크놀로지스 게엠베하 신규 조작된 t 세포 수용체 및 이를 사용하는 면역 요법
DE102017125888A1 (de) 2017-11-06 2019-05-23 Immatics Biotechnologies Gmbh Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
BR112020016176A2 (pt) 2018-02-09 2022-02-22 Immatics Us Inc Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
BR112020025589A2 (pt) 2018-06-19 2021-03-23 Dsm Ip Assets B.V. variantes de enzima lipolítica
EP3914612A1 (en) 2019-01-22 2021-12-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class ii-restricted t cell receptors against ras with g12r mutation
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
US12011459B2 (en) 2019-06-06 2024-06-18 Immatics US, Inc. Methods for manufacturing T cells by direct sorting and compositions thereof
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CA3168729A1 (en) 2020-02-24 2021-09-02 Melinda MATA Methods for expanding t cells for the treatment of cancer and related malignancies
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20230405046A1 (en) * 2020-03-16 2023-12-21 Biontech Cell & Gene Therapies Gmbh Antigen-specific t cell receptors and t cell epitopes
WO2021252517A1 (en) * 2020-06-09 2021-12-16 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Cd8多肽、組合物及其使用方法
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
JP2024534825A (ja) 2021-08-24 2024-09-26 イマティクス ユーエス,アイエヌシー. 条件付きリガンド交換により産生されたペプチドmhc複合体を使用する免疫細胞の選択
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於t細胞療法之t細胞群體的單核球耗盡
WO2023056240A2 (en) 2021-09-28 2023-04-06 Frontaim Biomedicines, Inc. Multiple formats of molecular complexes
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
EP4448108A1 (en) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Adoptive cell therapy combination treatment and compositions thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4514829A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN117946246B (zh) * 2023-02-23 2024-08-06 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2026046995A1 (en) * 2024-08-28 2026-03-05 Pairx Bio Pte. Ltd T cell receptors and uses thereof
CN120718134B (zh) * 2025-08-25 2025-12-26 北京立康生命科技有限公司 靶向col6a3肽的t细胞受体及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2006023382A2 (en) * 2004-08-23 2006-03-02 Albert Einstein College Of Medicine Of Yeshiva University Collagen vi and cancer
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
US8105831B2 (en) * 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US9228007B1 (en) * 2010-03-11 2016-01-05 The Regents Of The University Of California Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
ES2745472T3 (es) * 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Receptores de células T anti-virus del papiloma humano 16 E6
KR20170032406A (ko) * 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
US10066002B2 (en) * 2014-11-05 2018-09-04 Genentech, Inc. Methods of producing two chain proteins in bacteria

Similar Documents

Publication Publication Date Title
JP2019528061A5 (enExample)
JP2026021299A5 (enExample)
JP2022058932A5 (enExample)
JP2017186337A5 (enExample)
ES2565481T3 (es) Anticuerpo anti-PlGF novedoso
JP2019511222A5 (enExample)
JP2022533796A5 (enExample)
JP2019536430A5 (enExample)
JP2025163055A5 (enExample)
JP2020511936A5 (enExample)
JP2021514664A5 (enExample)
JP2023139070A5 (enExample)
HRP20200383T1 (hr) Ciljana vezna sredstva protiv b7-h1
JP2020500523A5 (enExample)
JP2009505676A5 (enExample)
JP2020511152A5 (enExample)
JP2010531140A5 (enExample)
JP2016505513A5 (enExample)
JP2020512019A5 (enExample)
JP2012529281A5 (enExample)
JP2020510653A5 (ja) Ceaを標的にする多重特異性結合タンパク質
JP2016521692A5 (enExample)
JP2011518886A5 (enExample)
JP2017503480A5 (enExample)
JP2022548764A5 (enExample)